Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.66M | $2.69M | $3.67M | — | — | — | — | $4.91M | $5.82M | $5.21M |
| Revenue growth | — | -42.2% | 36.5% | — | — | — | — | — | 18.5% | -10.5% |
| Gross profit | $1.94M | $146K | — | — | — | — | — | — | — | — |
| Gross margin | 41.7% | 5.4% | — | — | — | — | — | — | — | — |
| Operating income | -$19.7M | -$20.7M | -$8.76M | -$3.66M | -$9.58M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| Operating margin | -423.2% | -769.2% | -238.7% | — | — | — | — | -271.1% | -252.3% | -293.5% |
| Net income | -$22.0M | -$22.7M | -$12.6M | -$10.9M | -$8.24M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Net margin | -473.5% | -843.7% | -344.2% | — | — | — | — | -271.0% | -222.8% | -429.4% |
| EPS (diluted) | -$1.28 | -$8.23 | -$86.98 | -$8.27 | -$1.86 | -$1.11 | -$11.58 | -$4.24 | -$2.34 | -$0.29 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.5M | -$18.1M | -$12.0M | -$5.91M | -$8.43M | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M |
| Capital expenditures | $67.0K | $295K | $133K | $67.0K | — | — | — | $160K | $146K | $67.0K |
| Free cash flow | -$19.6M | -$18.4M | -$12.1M | -$5.97M | — | — | — | -$13.0M | -$10.7M | -$20.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.6M | $9.55M | $5.26M | $17.6M | $8.35M | $18.4M | $18.1M | $8.55M | $76.0K | $4.26M |
| Total assets | $34.6M | $31.6M | $24.0M | $23.2M | $12.1M | $22.0M | $23.9M | $11.4M | $6.63M | $16.3M |
| Total liabilities | $23.6M | $18.6M | $18.8M | $22.1M | $9.07M | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M |
| Long-term debt | — | — | — | — | — | $5.00M | $3.79M | — | — | — |
| Shareholders' equity | $11.0M | $13.0M | $5.22M | $1.16M | $3.03M | $10.8M | $6.45M | -$1.35M | -$8.95M | $4.00M |
| Retained earnings | -$379M | -$402M | -$414M | -$425M | -$434M | -$447M | -$467M | -$481M | -$493M | -$516M |
| Shares (wtd avg diluted) | 200M | 5.78M | 61.6M | 3.88M | 6.75M | 12.1M | 1.75M | 3.14M | 7.70M | 77.8M |
Every figure is extracted from PLUS THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.